| |
Dependable and flexible.
As a leading provider of active ingredients and excipients, BASF has extensive expertise
in the field of pharmaceuticals. We also utilize this for the production of solid,
semi-solid and liquid dosage forms. Our technologies and production facilities are
available to our customers for contract manufacturing and packaging at our site
in Shreveport, Louisiana (USA). The site offers more than 20 years’ experience with
branded, generic and over-the-counter pharmaceutical products and has a strong record
of compliance with the U.S. Food and Drug Administration, the Drug Enforcement Agency
and the Canadian Health Protection Branch. Use of state-of-the-art processes enables
cost-effective, on-time deliveries to our customers with the highest level of quality.
The site includes more than 300,000 square feet of manufacturing, laboratory and
warehouse space. It has a wide variety of production resources, from pilot-scale
to commercial-scale production volumes. Our facility complies with all cGMP guidelines
and is able to process up to Schedule II compounds.
Pharmaceuticals in solid form: powders, granulation, tablets, capsules |
top |
In three state-of-the-art granulation rooms, wet or dry granulations are produced
via high-shear or low-shear granulation processes and are subsequently dried using
the fluidized-bed process. Granulation mixes range in size from approximately 80
kg to 300 kg. The plant has a variety of compression equipment that compresses the
granulation into tablets or caplets. Hard-shell gelatin capsules are filled with
powders and pellets using a modern encapsulation machine. Both aqueous and solvent
coating technology is available for film coating. Additional capabilities include
a high-speed printer, tablet sorter and metal detector.
Pharmaceuticals in semi-solid form:
creams, gels, ointments |
top |
Our jacketed and non-jacketed vessels allow creams, gels and ointments to be produced
in batch volumes up to 3,000 kg. Once produced, product can then be packaged in
tubes or jars for finished packaging.
Pharmaceuticals in liquid form:
solutions, suspensions, emulsions |
top |
A colloid mill and various sizes of tanks with agitators ranging from 800 l to 5,000
l are available for the production of solutions, suspensions and dispersions.
Pharmaceutical development
|
top |
A 2,700 square foot, self-contained cGMP pilot plant is available and fully equipped
to perform laboratory, pilot and small-scale batches. We also offer our customers
support for the pharmaceutical development of new preparations as well as the optimization
of already established products. Our staff is experienced in writing and executing
protocols in support of process, cleaning and equipment validation and providing
support in technology transfers for pilot to commercial-scale production. We concentrate
on giving new or familiar active ingredients a suitable pharmaceutical form as well
as optimizing production processes and formulation where BASF can draw on its unique,
proven expertise with active ingredients such as BASF’s own production for ibuprofen
and for special processes utilizing pharmaceutical technology, in particular, for
tablet production.
As a customer-focused, make-to-order contract manufacturer, BASF offers a comprehensive
and complete service, including finished dose packaging. At Shreveport, the five
separate packaging lines with environmentally controlled fill rooms reflect state-of-the-art
pharmaceutical technology. Thanks to automated and computer-aided processes, more
than eight billion tablets can be packaged each year. Tablets and liquids are packaged
in small- to large-count bottles. Creams, gels and ointments are packaged in tubes
or jars. A high-speed over-the-counter packaging line is specially designed to offer
three-level tamper-evident packaging, including induction seal, neckband and unit
carton application. Products can be custom-packaged to our customer’s specifications
in compliance with all regulatory requirements.
Computer-assisted order handling ensures that the products are promptly shipped
to customer’s request with all required documentation. Thanks to our central location
and close proximity to major transportation routes, we are able to supply all the
major North American centers from Shreveport within a very short time, giving our
customers access to the important pharmaceutical market in North America.
|
|
 |
News |
| |
|
April 30, 2008:
BASF sells its Shreveport site and related contract manufacturing business to Dr. Reddy's Laboratories
(english, deutsch) January 18, 2008:
BASF appoints Folker Ruchatz as head of its custom synthesis business
(english, deutsch)
|
|
 |
Video |
 |
| |
 |
Product Search |
|
|
|